Loading
NASDAQHealthcareBiotechnology
Latest quote
$3.74
−$0.12 · -3.11%
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
Previous close
$3.74
−$0.12 · -3.11%
After-hours
$3.78
+$0.04 · +1.07%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
Day range
Current $3.74
52-week range
Current $3.74
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
39
Expensive
Sentiment
76
Bullish
Risk
63
High Risk
Momentum
41
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
Day range
Current $3.74
52-week range
Current $3.74
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 316.95K USD | 2.08M USD |
| Cost of goods sold | 698.89K USD | — | — | 158.12K USD | 1.15M USD |
| Gross profit | −698.89K USD | — | — | 158.83K USD | 926.89K USD |
| Research and development | 42.05M USD | 47.96M USD | 41.62M USD | 36.27M USD | 26.54M USD |
| Selling, general, and administrative | 17.3M USD | 16.08M USD | 16.76M USD | 15.61M USD | 8.27M USD |
| Operating expenses | 58.68M USD | 64.07M USD | 58.41M USD | 51.9M USD | 34.81M USD |
| Interest income | 3.04M USD | 2.59M USD | 3.61M USD | 1.01M USD | 169.9K USD |
| Depreciation and amortization | 353.78K USD | 385.07K USD | 352.08K USD | 277.25K USD | 159.07K USD |
| Operating income | −59.38M USD | −64.07M USD | −58.41M USD | −51.74M USD | −33.89M USD |
| Net income | −56.02M USD | −61.04M USD | −53.47M USD | −50.51M USD | −33.54M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI8.1M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM5.57M0.01%77.7B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF3.15M0.00%95.4B USD0.05%$233.13-0.15%
iShares Biotechnology ETFIBB1.68M0.02%10.41B USD0.44%$200.48-1.41%
Vanguard Russell 2000 ETFVTWO1.53M0.01%18B USD0.06%$112.1-0.10%
iShares Micro-Cap ETFIWC683.46K0.05%1.32B USD0.60%$182.79-0.31%
ALPS Medical Breakthroughs ETFSBIO314.83K0.17%188.26M USD0.50%$53.945-0.34%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM280K0.24%116.54M USD0.73%$15.90-0.44%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCALPS Medical Breakthroughs ETFSBIOEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
